# Attention-deficit/hyperactivity disorder across the female hormonal life cycle: a scoping review of symptoms, diagnosis, and treatment from puberty to menopause - URL: https://alisanburak.com/en/wcp-2026-posterler/so456 - Language: en - Last updated: not specified - Page title: Attention-deficit/hyperactivity disorder across the female hormonal life cycle: a scoping review of symptoms, diagnosis, and treatment from puberty to menopause | WCP 2026 Summary > ADHD symptoms consistently worsen during periods of declining estrogen, yet menopause and hormonal contraception remain seriously understudied. This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/so456) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. SO456 Brief Oral Poster PresentationPerinatal and Women's HealthScoping review # Attention-deficit/hyperactivity disorder across the female hormonal life cycle: a scoping review of symptoms, diagnosis, and treatment from puberty to menopause ATTENTION-DEFICIT/HYPERACTIVITY DISORDER ACROSS THE FEMALE HORMONAL LIFESPAN: A SCOPING REVIEW OF SYMPTOMS, DIAGNOSIS AND TREATMENT FROM PUBERTY TO MENOPAUSE Presenter: Hurmat Ullah Khan Syed Country: United Kingdom Institution: Mental Health and Wellbeing Services Session: 4540 - PARALLEL SHORT ORAL POSTER SESSIONS: CHILD & DEVELOPMENTAL PSYCHIATRY - Part VI Date: Sat, 26.09.2026 ADHD symptoms consistently worsen during periods of declining estrogen, yet menopause and hormonal contraception remain seriously understudied. The study aims to map the evidence on the symptoms, diagnosis, and treatment of attention-deficit/hyperactivity disorder (ADHD) in women across hormonal life stages; because estrogen regulates dopaminergic tone, hormonal transitions were hypothesized to alter symptoms and treatment response. A scoping review was conducted in accordance with the PRISMA-ScR guidelines; PubMed/MEDLINE, Embase, and CINAHL were searched from inception through 2026, combining ADHD terms with terms related to the menstrual cycle, ovarian hormones, contraception, pregnancy and the postpartum period, and menopause. The search yielded 12,331 records, of which 10,530 were screened after duplicates were removed; studies examining prenatal exposure and child outcomes were excluded, and the evidence was mapped across five hormonal stages. The distribution of evidence was markedly uneven: during low-estrogen periods (the late luteal phase, the postpartum period, and perimenopause), ADHD symptoms and low mood worsen, reduced response to stimulants is reported, and premenstrual dysphoric disorder (PMDD) is substantially more common in women with ADHD. A search focused on the least-studied stages identified approximately 15 studies addressing perimenopause and menopause and fewer than 5 studies directly addressing hormonal contraception in women with ADHD. Moreover, much of the literature appearing under these topics examines ADHD risk in women's children rather than the women themselves, while evidence on treatment during menopause is derived largely from stimulant studies in women without an ADHD diagnosis. The findings highlight the need for hormone-informed, life-stage-specific clinical guidance and prospective studies focused on women; in clinical practice, asking about menstrual cycle phase, contraception, and menopausal status is recommended when ADHD symptom control fluctuates. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1277) How to cite this study APA 7: Syed, H. U. K., et al. (2026, September 26). Attention-deficit/hyperactivity disorder across the female hormonal lifespan: a scoping review of symptoms, diagnosis and treatment from puberty to menopause [Poster presentation]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1277 Vancouver: Syed HUK, et al. Attention-deficit/hyperactivity disorder across the female hormonal lifespan: a scoping review of symptoms, diagnosis and treatment from puberty to menopause [poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1277 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Dikkatsizlik ve hiperaktivitenin ötesinde: kadınlarda DEHB'nin yeterince tedavi edilmeyen bir boyutu olarak duygusal disregülasyon](https://alisanburak.com/en/wcp-2026-posterler/ev0078) - [Gebelikte anne tiroid işlev bozukluğunun bebekte otizm spektrum bozukluğuyla ilişkisi: sistematik derleme ve meta-analiz](https://alisanburak.com/en/wcp-2026-posterler/ev0181) - [Hafif ve orta düzey obstetrik yük ile doğum sonrası kırk beşinci ayda boyutsal ruh sağlığı sonuçları](https://alisanburak.com/en/wcp-2026-posterler/ev0237) - [Portekiz toplumunda kabul görmeyen yas ölçeğinin geliştirilmesi ve geçerliğine ilişkin ön veriler](https://alisanburak.com/en/wcp-2026-posterler/ev0290) - [Gebelikte olumlu anne ruh sağlığı ile çocukta psikopatoloji ve sosyoduygusal gelişim: olası mekanizmalar ve yeni yönelimler](https://alisanburak.com/en/wcp-2026-posterler/ev0419) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/so456 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim